Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2004 2
2005 2
2006 2
2007 2
2008 2
2009 4
2010 3
2011 3
2012 5
2013 5
2014 4
2015 3
2016 3
2017 2
2018 2
2019 3
2020 2
2021 5
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Endoscopic ultrasound and pancreas divisum.
Rana SS, Gonen C, Vilmann P. Rana SS, et al. Among authors: gonen c. JOP. 2012 May 10;13(3):252-7. JOP. 2012. PMID: 22572127 Free article. Review.
miR-4734 conditionally suppresses ER stress-associated proinflammatory responses.
Michael D, Feldmesser E, Gonen C, Furth N, Maman A, Heyman O, Argoetti A, Tofield A, Baichman-Kass A, Ben-Dov A, Benbenisti D, Hen N, Rotkopf R, Ganci F, Blandino G, Ulitsky I, Oren M. Michael D, et al. Among authors: gonen c. FEBS Lett. 2023 May;597(9):1233-1245. doi: 10.1002/1873-3468.14548. Epub 2022 Dec 11. FEBS Lett. 2023. PMID: 36445168 Free article.
A rare cause of rectal bleeding.
Aslan E, Gonen C. Aslan E, et al. Among authors: gonen c. Acta Gastroenterol Belg. 2018 Apr-Jun;81(2):350. Acta Gastroenterol Belg. 2018. PMID: 30024717 Free article. No abstract available.
Clinical and laboratory features of COVID-19: Predictors of severe prognosis.
Bastug A, Bodur H, Erdogan S, Gokcinar D, Kazancioglu S, Kosovali BD, Ozbay BO, Gok G, Turan IO, Yilmaz G, Gonen CC, Yilmaz FM. Bastug A, et al. Among authors: gonen cc. Int Immunopharmacol. 2020 Nov;88:106950. doi: 10.1016/j.intimp.2020.106950. Epub 2020 Sep 9. Int Immunopharmacol. 2020. PMID: 32919217 Free PMC article.
55 results